Letter to the Editor
Reply: Neuropsychiatric symptoms in Parkinson's disease†
Potential conflict of interest: Dr. Aarsland received honorarium from GE Health, Merck Serono, Lundbeck, Novartis, and Diagenic; received research support from Lundbeck, Merck, and Serono; and serves on the advisory board for Diagenic. Dr. Marsh is supoprted by NIH grats RO1-MH069666; receives royalties from Taylor and Francis/Informa. Dr. Shrag participated in a trial by ACADIA Pharmaceuticals, Inc. that was related to this article; serves as a consultant for Servier (Institut De Recherches Internationales Servier and ADIR); serves on the advisory board for Osmotica Pharmaceuticals.
No abstract is available for this article.